iiinova — where your digital self keeps evolving

Patrick Bryant

@patrickbryant1.bsky.social

Assistant Professor at Stockholm University. Dedicated Scientist.

Patrick Bryant @patrickbryant1.bsky.social · 26/08/2026

Can molecular glues be designed rather than discovered by chance? We built EvoBind-multimer to design small (6-10 AAs) cyclic peptide glues directly from protein sequences. We validate de novo VHL-KRAS and VHL-BRD4 glues in cells and patient-derived tumoroids.

230

Patrick Bryant @patrickbryant1.bsky.social · 07/02/2026

🕊️ Structural Acceleration Does a bigger genome mean faster structural evolution? No. We found lineage-specific bursts of structural innovation in Birds (Aves) and Ants (Hymenoptera) that are distinct from genomic expansion. (4/5)

130

Patrick Bryant @patrickbryant1.bsky.social · 07/02/2026

🐁 Stop guessing your model organism. Our new search engine allows you to rank model organisms by their structural fidelity to specific human pathways. Case Study: For Fanconi Anaemia, Mouse is perfect. Yeast fails. C. elegans is a hidden gem. (2/5)

180

Patrick Bryant @patrickbryant1.bsky.social · 07/02/2026

Introducing The Structural History of Eukarya (SHE): The first proteome-scale phylogeny constructed entirely from 3D structure. We computed 300 trillion alignments across 1,542 species to map the tree of life. 🧵👇 (1/5)

28439

Patrick Bryant @patrickbryant1.bsky.social · 03/10/2025

The future of drug design is in AI. RareFoldGPCR: Agonist Design Beyond Natural Amino Acids. Paper: www.biorxiv.org/content/10.1... Code: github.com/patrickbryan...

020

Patrick Bryant @patrickbryant1.bsky.social · 22/07/2025

Our study where we develop EvoBind2: Design of linear and cyclic peptide binders from protein sequence information is now published! www.nature.com/articles/s42...

152

Patrick Bryant @patrickbryant1.bsky.social · 06/07/2025

Now published: our study on human-pathogen protein-protein interactions! We identify 30 interactions with an expected TM-score ≥0.9, tripling the structural coverage in these networks. One novel interaction was validated with mass spectrometry. journals.plos.org/ploscompbiol...

240

Patrick Bryant @patrickbryant1.bsky.social · 09/06/2025

Our latest work is out: we designed dual GLP1R/GCGR agonists—cyclic peptides that activate both metabolic receptors, entirely from sequence alone. This has never been done before. www.biorxiv.org/content/10.1...

051

Patrick Bryant @patrickbryant1.bsky.social · 25/05/2025

Happy to release our breakthrough AI-model: RareFold, which predicts and designs proteins with noncanonical AAs. With EvoBindRare, we designed linear & cyclic peptide binders with high affinity & novel binding modes, wet lab validated. 📄 biorxiv.org/content/10.1... 💻 github.com/patrickbryan...

2194